SCHEMBL21703326

SCHEMBL21703326

Nc1cccn(Cc2nc3cccc(O)c3s2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.39
VEGFA P15692 1/20 0.39
AKR1B1 P15121 4/20 0.38
KDM4E B2RXH2 4/20 0.37
S1PR2 O95136 4/20 0.37
ALDH1A1 P00352 4/20 0.37
GAA P10253 4/20 0.37
HPGD P15428 4/20 0.37
GLA P06280 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TDP1 Q9NUW8 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
NPC1 O15118 2/20 0.37
ATM Q13315 2/20 0.37
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25947188 0.83 MAP4K1 (0.39) AKR1B1KDM4ES1PR2ALDH1A1GAA
SCHEMBL21685793 0.81 TLR8 (0.37) AKR1B1KDM4ES1PR2ALDH1A1GAA
SCHEMBL21685712 0.80 SMN1; SMN2 (0.53) AKR1B1KDM4ES1PR2ALDH1A1GAA
SCHEMBL21702992 0.79 MAP4K1 (0.52) AKR1B1KDM4ES1PR2ALDH1A1GAA
SCHEMBL21702994 0.79 MAP4K1 (0.40) AKR1B1KDM4ES1PR2ALDH1A1GAA
SCHEMBL21702985 0.78 MAP4K1 (0.52) AKR1B1KDM4ES1PR2ALDH1A1GAA
SCHEMBL25947354 0.76 MAP4K1 (0.40) AKR1B1KDM4ES1PR2ALDH1A1GAA
SCHEMBL21684882 0.74 MAPK14 (0.47) MAP4K1
SCHEMBL21684178 0.73 DHFR (0.50) KDM4EALDH1A1GAAHPGDMAPT
SCHEMBL31304006 0.73 DHFR (0.50) KDM4EALDH1A1GAAHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020033784-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC. (US) 2020-02-13 WO disclosed